King Pharmaceuticals® Inc.
Research and Development
CentreGreen Two, Suite 300
4000 CentreGreen Way
Cary, NC 27513

Eric G. Carter, PhD, MD
Chief Science Officer

July 31, 2009

Dear Healthcare Professional:

We would like to inform you that after careful consideration, King Pharmaceuticals®, Inc. will soon discontinue the manufacture of INTAL® Inhaler (cromolyn sodium inhalation aerosol). King will continue to accept orders for INTAL until current inventories are exhausted, so the exact date of product unavailability is not known. This action is not the result of any safety or efficacy issues regarding this product.

This decision is based upon many factors, including our inability to identify a qualified manufacturer for chlorofluorocarbon propellant inhalers and our inability, despite best efforts, to reformulate INTAL® to a chlorofluorocarbon-free or hydrofluoroalkane (HFA) propellant formulation. We are providing this notification to you as a healthcare professional so that patients currently using INTAL can be effectively and efficiently transitioned to alternative therapies. Because of the planned phase out of INTAL, please refrain from initiating treatment with this product.

INTAL® will remain available through pharmacies and wholesalers until current supplies are depleted. INTAL® is distributed through King Pharmaceuticals®, Inc. No additional product will be available after King, pharmacy and wholesaler supplies are exhausted.

If you have any questions or concerns, you may contact our Professional Information Services Department at 800-776-3637.

INTAL® Inhaler is a prophylactic agent indicated in the management of patients with bronchial asthma.

Important Safety Information:

INTAL® Inhaler is contraindicated in those patients who have shown hypersensitivity to cromolyn sodium or other ingredients in this preparation. **Intal Inhaler has no role in the treatment of an acute attack of asthma, especially status asthmaticus. Severe anaphylactic reactions can occur after cromolyn sodium administration. The recommended dosage should be decreased in patients with decreased renal or hepatic function. Intal Inhaler should be discontinued if the patient develops eosinophilic pneumonia (or pulmonary infiltrates with eosinophilia). Because of the propellants in this preparation, it should be used with caution in patients with coronary artery disease or a history of cardiac arrhythmias.** In view of the biliary and renal routes of excretion for cromolyn sodium, consideration should be given to decreasing the dosage or discontinuing the administration of the drug in patients with impaired renal or hepatic function. Common adverse reactions include throat irritation or dryness, bad taste, cough, wheeze, and nausea.

Sincerely,

Eric Carter, PhD, MD
Chief Science Officer

Please see accompanying full Prescribing Information.